• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

按种族/族裔划分的国家乳腺癌和宫颈癌早期检测项目中乳腺癌筛查的估计健康结果。

Estimated health outcomes of breast cancer screening in the national breast and cervical cancer early detection program by race/ethnicity.

作者信息

Ekwueme Donatus U, Reagan Kelly A, Kao Szu-Yu, Dasari Sabitha, Kenney Kristy M, Wu Manxia, Thompson Trevor D, Miller Jacqueline W

机构信息

Centers for Disease Control and Prevention, Division of Cancer Prevention and Control, Atlanta, GA, USA.

Alan Shawn Feinstein College of Education, University of Rhode Island, Kingston, Rhode Island, USA.

出版信息

Cancer Causes Control. 2025 May 6. doi: 10.1007/s10552-025-02006-2.

DOI:10.1007/s10552-025-02006-2
PMID:40327212
Abstract

PURPOSE

To estimate the number of screenings received, life-years (LYs) saved, and number of screenings per LY saved per woman who participated in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) (Program) compared with those who did not participate (no Program).

METHODS

We developed a time-to-event simulation model to compare the outcomes of women participating in the Program vs. no Program, categorized by race/ethnicity. Model input parameters included data from the Program's minimum data elements, United States Cancer Statistics, National Health Interview Survey, and published literature. The Program's impact was calculated as the difference in LYs between the Program and no Program using data from 2010 to 2019.

RESULTS

Among 1 million women of all races/ethnicities who participated in the NBCCEDP in the last 10 years, 457,152 (standard deviation [SD]: 848) received more screenings than those who did not participate. These participants saved an average of 0.027 LYs per woman screened. In addition, we estimated that about 17 screenings would be required to save an additional 1 LY per woman screened in the Program compared with no Program. Per woman screened by race/ethnicity, non-Hispanic Black women had the highest estimated 0.075 LYs saved, followed by Hispanic women with 0.025 LYs, non-Hispanic White with 0.014 LYs, and non-Hispanic American Indian/Alaska Native and Asian/Pacific Islander had the least health outcome with 0.011 LYs.

CONCLUSION

The reported findings underscore the importance of providing preventive health services to populations that might not otherwise have access to these services.

摘要

目的

评估参与国家乳腺癌和宫颈癌早期检测项目(NBCCEDP,简称“项目”)的女性与未参与该项目(无项目组)的女性相比,接受筛查的次数、挽救的生命年数(LYs)以及每挽救1个生命年所需的筛查次数。

方法

我们建立了一个事件发生时间模拟模型,以比较按种族/族裔分类的参与项目女性与无项目组女性的结果。模型输入参数包括来自项目最小数据元素、美国癌症统计数据、国家健康访谈调查以及已发表文献的数据。利用2010年至2019年的数据,将项目的影响计算为项目组与无项目组之间生命年数的差异。

结果

在过去10年中参与NBCCEDP的100万各种族/族裔女性中,457,152名(标准差[SD]:848)接受的筛查比未参与者更多。这些参与者平均每位接受筛查的女性挽救了0.027个生命年。此外,我们估计,与无项目组相比,在该项目中每位接受筛查的女性要额外挽救1个生命年大约需要17次筛查。按种族/族裔划分,在接受筛查的女性中,非西班牙裔黑人女性挽救的生命年数估计最高,为0.075个,其次是西班牙裔女性,为0.025个,非西班牙裔白人女性为0.014个,非西班牙裔美国印第安人/阿拉斯加原住民以及亚裔/太平洋岛民的健康结果最差,为0.011个。

结论

报告结果强调了为那些可能无法获得这些服务的人群提供预防性健康服务的重要性。

相似文献

1
Estimated health outcomes of breast cancer screening in the national breast and cervical cancer early detection program by race/ethnicity.按种族/族裔划分的国家乳腺癌和宫颈癌早期检测项目中乳腺癌筛查的估计健康结果。
Cancer Causes Control. 2025 May 6. doi: 10.1007/s10552-025-02006-2.
2
Racial and ethnic disparities in fecundability: a North American preconception cohort study.生育力方面的种族和族裔差异:一项北美孕前队列研究。
Hum Reprod. 2025 Apr 17. doi: 10.1093/humrep/deaf067.
3
Surveillance for Violent Deaths - National Violent Death Reporting System, 50 States, the District of Columbia, and Puerto Rico, 2022.暴力死亡监测——2022年全国暴力死亡报告系统,50个州、哥伦比亚特区和波多黎各
MMWR Surveill Summ. 2025 Jun 12;74(5):1-42. doi: 10.15585/mmwr.ss7405a1.
4
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
5
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
6
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
7
Individual- and Group-Level Disparities Between Racial and Ethnic Groups in Lung Cancer Screening Eligibility Criteria.肺癌筛查资格标准中种族和族裔群体在个体及群体层面的差异。
JAMA Netw Open. 2025 Mar 3;8(3):e252172. doi: 10.1001/jamanetworkopen.2025.2172.
8
Sexual Harassment and Prevention Training性骚扰与预防培训
9
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
10
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.

本文引用的文献

1
Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement.乳腺癌筛查:美国预防服务工作组推荐声明。
JAMA. 2024 Jun 11;331(22):1918-1930. doi: 10.1001/jama.2024.5534.
2
Barriers to Breast Cancer-Screening Adherence in Vulnerable Populations.弱势群体乳腺癌筛查依从性的障碍
Cancers (Basel). 2023 Jan 18;15(3):604. doi: 10.3390/cancers15030604.
3
Targeted therapy for breast cancer: An overview of drug classes and outcomes.乳腺癌的靶向治疗:药物类别与治疗结果概述
Biochem Pharmacol. 2022 Oct;204:115209. doi: 10.1016/j.bcp.2022.115209. Epub 2022 Aug 14.
4
Health insurance status and cancer stage at diagnosis and survival in the United States.美国的健康保险状况与诊断时的癌症分期和生存情况。
CA Cancer J Clin. 2022 Nov;72(6):542-560. doi: 10.3322/caac.21732. Epub 2022 Jul 13.
5
Value of the Immunization Program for Children in the 2017 US Birth Cohort.2017 年美国出生队列儿童免疫计划的价值。
Pediatrics. 2022 Sep 1;150(3). doi: 10.1542/peds.2021-056007.
6
Breast cancer in the era of precision medicine.精准医学时代的乳腺癌。
Mol Biol Rep. 2022 Oct;49(10):10023-10037. doi: 10.1007/s11033-022-07571-2. Epub 2022 Jun 22.
7
DCIS: Risk Assessment in the Molecular Era.DCIS:分子时代的风险评估。
Semin Radiat Oncol. 2022 Jul;32(3):189-197. doi: 10.1016/j.semradonc.2022.01.005.
8
Trends in Breast Cancer Incidence, by Race, Ethnicity, and Age Among Women Aged ≥20 Years - United States, 1999-2018.美国≥20 岁女性中乳腺癌发病率的种族、民族和年龄趋势 - 1999-2018 年。
MMWR Morb Mortal Wkly Rep. 2022 Jan 14;71(2):43-47. doi: 10.15585/mmwr.mm7102a2.
9
A comparison of time to event analysis methods, using weight status and breast cancer as a case study.使用体重状况和乳腺癌作为案例研究比较生存时间分析方法。
Sci Rep. 2021 Jul 7;11(1):14058. doi: 10.1038/s41598-021-92944-z.
10
Recent Changes in the Patterns of Breast Cancer as a Proportion of All Deaths According to Race and Ethnicity.根据种族和民族,乳腺癌占所有死亡人数比例的模式最近发生的变化。
Epidemiology. 2021 Nov 1;32(6):904-913. doi: 10.1097/EDE.0000000000001394.